title: Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry.
abstract: Hyperlipidemia occurs frequently after heart transplantation, and accelerated coronary artery disease remains the major cause of morbidity and mortality in patients who survive more than 1 year after heart transplantation. However, the risks and benefits of lipid-lowering therapy after heart transplantation remain poorly defined, and national guidelines for lipid-lowering drug therapy do not specifically address treatment of dyslipidemia in transplant recipients. Since the initial reports in the 1980s of rhabdomyolysis in heart transplant patients receiving high-dosage lovastatin, results of 11 post-transplantation series that used lovastatin, simvastatin, or pravastatin at lower dosages as drug monotherapy have been published. These studies have shown an overall 1% incidence of rhabdomyolysis, defined as creatine kinase > 10 times the upper limit of normal plus muscle symptoms. One randomized, controlled prospective trial has investigated the effects of lipid-lowering pharmacotherapy on patient outcome in cardiac transplant recipients. At 1-year follow-up in this nonblinded, single-center trial, patients treated with pravastatin (20 or 40 mg/day) initiated within 2 weeks of transplantation had a significant reduction in mortality rate and a significantly lower incidence of transplant arteriopathy. A number of important issues remain unanswered regarding treatment guidelines in patients with hyperlipidemia after heart transplantation. In January 1995 we began the Heart Transplant Lipid Registry, with 12 participant centers, to gather data prospectively on the efficacy and safety of lipid-lowering drugs in the treatment of dyslipidemia after heart transplantation.
authors.affiliation: Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA.
authors.forename: C M
authors.initials: CM
authors.lastname: Ballantyne
authors.forename: R C
authors.initials: RC
authors.lastname: Bourge
authors.forename: L J
authors.initials: LJ
authors.lastname: Domalik
authors.forename: H J
authors.initials: HJ
authors.lastname: Eisen
authors.forename: D P
authors.initials: DP
authors.lastname: Fishbein
authors.forename: S H
authors.initials: SH
authors.lastname: Kubo
authors.forename: K D
authors.initials: KD
authors.lastname: Lake
authors.forename: B
authors.initials: B
authors.lastname: Radovancevic
authors.forename: D O
authors.initials: DO
authors.lastname: Taylor
authors.forename: H O
authors.initials: HO
authors.lastname: Ventura
authors.forename: C W
authors.initials: CW
authors.lastname: Yancy
authors.forename: J B
authors.initials: JB
authors.lastname: Young
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D016027:Heart Transplantation; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D008148:Lovastatin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000188:drug therapy*; D017035:Pravastatin / Q000627:therapeutic use*; D012042:Registries; D019821:Simvastatin; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D008148:Lovastatin; D019821:Simvastatin; D017035:Pravastatin